Business Context and Reporting Period
This Form 8-K Current Report, dated April 23, 2020, details material definitive agreements entered into by Zimmer Biomet Holdings, Inc. (ZBH) to secure liquidity and amend existing debt covenants. The report covers actions taken on April 23, 2020, and April 28, 2020, involving new credit facilities and amendments to existing revolving credit and term loan agreements.
Key Financial Metrics and Debt Structure
- New Revolving Facility: Established a $1.0 billion unsecured revolving credit facility (2020 Revolving Facility) maturing on December 31, 2020.
- Interest Rates: Borrowings bear interest at floating rates (LIBOR or alternate base rate) plus a margin based on the Company's senior unsecured long-term debt credit rating.
- Existing Debt: The filing references existing Japanese Yen term loans totaling approximately JP¥33 billion (JP¥21.3 billion and JP¥11.7 billion) held by subsidiary Zimmer Biomet G.K.
- Liquidity Purpose: Proceeds from the new facility are designated for general corporate purposes.
Material Changes Versus Prior Period
The Company executed significant changes to its debt covenants and interest structures to accommodate current market conditions:
- Covenant Relaxation: The maximum permitted Consolidated Leverage Ratio (Indebtedness to EBITDA) was temporarily increased to 5.75 to 1.00 for periods ending between April 1, 2020, and December 31, 2020. This is an increase from the prior standard of 4.50 to 1.00.
- Cost of Borrowing: The interest rate margin on revolving loans and the facility fee were temporarily increased through March 31, 2021, reflecting the higher leverage tolerance.
- Covenant Alignment: Amendments to Japanese Yen term loans were made to align their covenants with the amended 2019 Credit Agreement, ensuring the temporary leverage ratio increase applies across these facilities.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue forecasts, or management commentary on operational outlook. However, the following risks and contingencies are noted:
- Covenant Compliance: The Company must maintain a Consolidated Leverage Ratio of no greater than 5.75 to 1.00 under the new 2020 Credit Agreement.
- Mandatory Prepayments: The 2020 Revolving Facility includes mandatory prepayment requirements and commitment reductions if the Company issues indebtedness above $25.0 million (subject to carve-outs).
- Future Adjustments: The leverage ratio is scheduled to step down to 5.00 to 1.00 for the period ending March 31, 2021, and 4.50 to 1.00 thereafter, unless a qualified material acquisition occurs after July 1, 2021.
Investor Verification Checklist
- Verify the Company's current Consolidated Leverage Ratio to ensure compliance with the new 5.75 to 1.00 threshold.
- Review the full text of the 2020 Credit Agreement (Exhibit 10.1) for specific definitions of "Consolidated Indebtedness" and "EBITDA."
- Monitor the Company's credit rating, as interest margins and facility fees are directly tied to the senior unsecured long-term debt rating.
- Check for any new indebtedness issuances exceeding $25.0 million that could trigger mandatory prepayments on the new revolving facility.
- Confirm the status of the Japanese Yen term loan amendments to ensure cross-default protections are aligned.